15th Jan 2016 07:51
LONDON (Alliance News) - Hutchison China MediTech Ltd on Friday said its Hutchison MediPharma Ltd drug research and development subsidiary has started a phase one trial in Australia on patients with haematological malignancies.
The trials will focus on Hutchison's HMPL-523 oral inhibitor and using the drug to treat patients who are unable to tolerate standard therapy options for haematological malignancies.
Hutchison said it hopes the trial will provide clinical proof-of-concept that modulation for the B-cell signalling pathway will provide a benefit to patients.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed